Altogether only ~16% of the disease-related proteins have been targeted by a drug (small molecule or biologic) nowadays. Estimates show that ~2% of the rest have been successfully knocked down by TPD in the recent years. Considering the relatively new and rapid emergence of TPD as a protein knock-down strategy, the percentage of successfully degraded targets seems rather impressive and expected to further increase.